Semaglutide generics launch pushes sales of GLP-1 drugs by 75% in 1 month, Pg16

Key Highlights:

• Sales of GLP-1 medicines in India surged by 75% following the launch of generic semaglutide in March 2026.
• Total semaglutide sales increased from 25,000 units in February to 1.7 lakh units in April 2026.
• Generic semaglutide sales reached 1.37 lakh units in April 2026, while innovator semaglutide sales increased to 32,000 units.

Detailed Insights:

• The introduction of generic semaglutide on March 21, 2026, after Novo Nordisk's patent expiry, significantly boosted the GLP-1 market.
• While sales of other GLP-1 drugs like liraglutide and tirzepatide decreased slightly, semaglutide sales experienced a seven-fold increase.
• Semaglutide and tirzepatide, both incretin mimetics, are approved for obesity treatment, with tirzepatide showing greater weight loss in trials.
• Despite the entry of generic versions, innovator products maintained their market share, indicating market expansion rather than cannibalization.
• The increased volume of generic semaglutide sales suggests improved affordability and aggressive marketing strategies.

Key Concepts Involved:

• GLP-1 (Glucagon-like Peptide-1): A hormone that stimulates insulin release and reduces glucagon secretion, used in diabetes and obesity treatments.
• Semaglutide: A GLP-1 receptor agonist used to treat type 2 diabetes and obesity by mimicking the effects of GLP-1.
• Tirzepatide: A dual GLP-1 and GIP receptor agonist, also used for diabetes and obesity management, showing promising weight loss results.
• Incretin Mimetics: Drugs that mimic the action of incretin hormones to enhance insulin secretion and regulate blood sugar levels.